Document Detail


Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angiotensin II antagonist for heart failure patients.
MedLine Citation:
PMID:  12174028     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers improve prognosis inpatients with chronic heart failure. Some patients, however, show little response to combined treatment with an ACE inhibitor and a beta-blocker. In addition, the ACE inhibitor cannot completely suppress angiotensin II production. Our objective was to examine whether replacing the ACE inhibitor with an angiotensin II antagonist can improve the condition of patients with chronic heart failure. METHODS: In 11 patients with chronic heart failure treated with an ACE inhibitor and a beta-blocker, who have had severe left ventricular dysfunction or high plasma level of natriuretic peptides, left ventricular dimension, and fractional shortening, plasma atrial and brain natriuretic peptide (ANP and BNP) levels were determined before and 3 months after the change of treatment. RESULTS: After substituting the ACE inhibitor with an angiotensin II antagonist, patients showed New York Heart Association functional class improvement, and significant decrease in left ventricular dimension and BNP. CONCLUSION: In patients with severe chronic heart failure treated with an ACE inhibitor and a beta-blocker, replacing the ACE inhibitor with an angiotensin II antagonist may be effective. However, this has to be confirmed by an adequately powered randomized controlled study.
Authors:
Y Hara; M Hamada; Y Shigematsu; T Ohtsuka; K Hiwada
Related Documents :
22375128 - Clinical application of heart rate variability after acute myocardial infarction.
8770078 - Angiotensin ii formation in dog heart is mediated by different pathways in vivo and in ...
12174028 - Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angioten...
22264598 - Red blood cell indices and development of hospital-acquired anemia during acute myocard...
12231588 - Myocardial infarction redefined: the new acc/esc definition, based on cardiac troponin,...
312978 - Prospective analysis of valvular replacement without venting the left ventricle.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of clinical pharmacy and therapeutics     Volume:  27     ISSN:  0269-4727     ISO Abbreviation:  J Clin Pharm Ther     Publication Date:  2002 Aug 
Date Detail:
Created Date:  2002-08-13     Completed Date:  2003-01-29     Revised Date:  2008-05-28    
Medline Journal Info:
Nlm Unique ID:  8704308     Medline TA:  J Clin Pharm Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  267-71     Citation Subset:  IM    
Affiliation:
The Second Department of Internal Medicine, Ehime University School of Medicine, Shigenobu-cho, Onsen-gun, Ehime, Japan. yujihara@m.ehime-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angiotensin II / antagonists & inhibitors*
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  therapeutic use*
Atrial Natriuretic Factor / analysis
Drug Therapy, Combination
Female
Heart Failure / etiology*,  pathology
Humans
Male
Middle Aged
Natriuretic Peptide, Brain / analysis
Treatment Outcome
Ventricular Dysfunction, Left
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 11128-99-7/Angiotensin II; 114471-18-0/Natriuretic Peptide, Brain; 85637-73-6/Atrial Natriuretic Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predictive performance of serum digoxin concentration in patients with congestive heart failure by a...
Next Document:  Health professionals' and consumers' views on the role of the pharmacy personnel and the pharmacy se...